You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾德生物(300685.SZ):上半年淨利升3.38%至8080.46萬元
格隆匯 07-27 20:39

格隆匯 7 月 27日丨艾德生物(300685.SZ)披露2020年半年度報告,實現營業收入2.83億元,同比增長6.44%;歸屬於上市公司股東的淨利潤8080.46萬元,同比增長3.38%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤6461.54萬元,同比增長0.12%;基本每股收益0.36元。

值得注意的是,報告期內,公司計提股權激勵費用2822.80萬元,若剔除報告期內股權激勵成本攤銷的影響(不考慮所得税影響),則歸屬於上市公司股東的淨利潤1.09億元,比去年同期增長24.56%(去年同期淨利潤數為8753.57萬元,即剔除股權激勵成本攤銷影響後的淨利潤)。

報告期內,在新冠肺炎疫情影響下,公司積極抗擊疫情的同時,採取多項舉措及時復工復產,保障生產經營工作的有序開展。公司繼續秉承“知而治之、艾德相伴”的經營宗旨,堅持創新、恪守合規,憑藉研發實力、銷售渠道、品牌效應以及領先產品等優勢,牢牢把握腫瘤精準醫療伴隨診斷市場發展的契機,以臨牀需求、患者受益為導向,持續不斷地推進技術創新,並通過加強市場推廣以及銷售隊伍建設等措施,促進公司主營業務持續、穩定、健康發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account